Compare RCEL & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCEL | SAVA |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | 226 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.0M | 96.1M |
| IPO Year | N/A | N/A |
| Metric | RCEL | SAVA |
|---|---|---|
| Price | $4.78 | $2.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $7.88 | $5.00 |
| AVG Volume (30 Days) | 227.9K | ★ 620.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.69 | N/A |
| Revenue Next Year | $49.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.22 | $1.15 |
| 52 Week High | $10.28 | $4.98 |
| Indicator | RCEL | SAVA |
|---|---|---|
| Relative Strength Index (RSI) | 54.06 | 43.01 |
| Support Level | $4.11 | $2.01 |
| Resistance Level | $5.89 | $2.29 |
| Average True Range (ATR) | 0.39 | 0.14 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 37.89 | 13.21 |
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.